Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Genetic-guided Risk Assessment and Management of Thyroid Cancer.

Literature DB >> 30717896

Genetic-guided Risk Assessment and Management of Thyroid Cancer.

Abstract

Controversies exist on how to optimally manage thyroid cancer because the prognosis is often uncertain based on clinical backgrounds. This can now be helped with prognostic genetic markers in thyroid cancer, exemplified by BRAF V600E and TERT promoter mutations, which have been well characterized and widely appreciated. The genetic duet of BRAF V600E/RAS and TERT promoter mutations is a most robust prognostic genetic pattern for poor prognosis of differentiated thyroid cancer. The high negative predictive values of the prognostic genetic markers are equally valuable. The best prognostic value of genetic markers in thyroid cancer is achieved through a clinical risk level-based and genotype-individualized manner.

Entities: CellLine Chemical Disease Gene Mutation Species

Keywords: BRAF V600E mutation; Genetic molecular marker; Prognosis; RAS mutation; Risk stratification; TERT promoter Mutation; Thyroid cancer

Mesh：

Substances：
Biomarkers, Tumor

Year: 2019 PMID： 30717896 PMCID： PMC6447365 DOI： 10.1016/j.ecl.2018.11.007

Source DB: PubMed Journal: Endocrinol Metab Clin North Am ISSN： 0889-8529 Impact factor: 4.741

70 in total

1. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis.

Authors: G Garcia-Rostan; R L Camp; A Herrero; M L Carcangiu; D L Rimm; G Tallini
Journal: Am J Pathol Date: 2001-03 Impact factor: 4.307

2. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

Authors: Edna T Kimura; Marina N Nikiforova; Zhaowen Zhu; Jeffrey A Knauf; Yuri E Nikiforov; James A Fagin
Journal: Cancer Res Date: 2003-04-01 Impact factor: 12.701

3. Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma.

Authors: G Garcia-Rostan; G Tallini; A Herrero; T G D'Aquila; M L Carcangiu; D L Rimm
Journal: Cancer Res Date: 1999-04-15 Impact factor: 12.701

4. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers.

Authors: Hiroyuki Namba; Masahiro Nakashima; Tomayoshi Hayashi; Naomi Hayashida; Shigeto Maeda; Tatiana I Rogounovitch; Akira Ohtsuru; Vladimir A Saenko; Takashi Kanematsu; Shunichi Yamashita
Journal: J Clin Endocrinol Metab Date: 2003-09 Impact factor: 5.958

5. BRAF mutations in papillary carcinomas of the thyroid.

Authors: Toshihiko Fukushima; Shinichi Suzuki; Miyuki Mashiko; Tohru Ohtake; Yoshiyuki Endo; Yuji Takebayashi; Koji Sekikawa; Koichi Hagiwara; Seiichi Takenoshita
Journal: Oncogene Date: 2003-09-25 Impact factor: 9.867

6. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.

Authors: Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Jorge Lima; Patrícia Castro; Ana Preto; Valdemar Máximo; Tiago Botelho; Raquel Seruca; Manuel Sobrinho-Simões
Journal: Oncogene Date: 2003-07-17 Impact factor: 9.867

7. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.

Authors: Ginesa Garcia-Rostan; Hongyu Zhao; Robert L Camp; Marina Pollan; Agustin Herrero; Javier Pardo; Ran Wu; Maria Luisa Carcangiu; Jose Costa; Giovanni Tallini
Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 44.544

8. BRAF mutation in papillary thyroid carcinoma.

Authors: Yoram Cohen; Mingzhao Xing; Elizabeth Mambo; Zhongmin Guo; Guogun Wu; Barry Trink; Uziel Beller; William H Westra; Paul W Ladenson; David Sidransky
Journal: J Natl Cancer Inst Date: 2003-04-16 Impact factor: 13.506

9. Mutations of the BRAF gene in human cancer.

Authors: Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal: Nature Date: 2002-06-09 Impact factor: 49.962

10. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.

Authors: Xiulong Xu; Roderick M Quiros; Paolo Gattuso; Kenneth B Ain; Richard A Prinz
Journal: Cancer Res Date: 2003-08-01 Impact factor: 12.701

13 in total

1. Metastases free thyroid cancer patients harbouring TERT mutations may benefit from a more intensive treatment and follow-up.

Authors: Alessandro Antonelli; Silvia Martina Ferrari; Giusy Elia; Armando Patrizio; Poupak Fallahi
Journal: Gland Surg Date: 2019-06

2. Risk Stratification in Differentiated Thyroid Cancer: From Detection to Final Follow-up.

Authors: R Michael Tuttle; Ali S Alzahrani
Journal: J Clin Endocrinol Metab Date: 2019-03-15 Impact factor: 5.958

3. Prognostic Impact of Microscopic Extra-Thyroidal Extension (mETE) on Disease Free Survival in Patients with Papillary Thyroid Carcinoma (PTC).

Authors: Nadia Bouzehouane; Pascal Roy; Myriam Decaussin-Petrucci; Mireille Bertholon-Grégoire; Chantal Bully; Agnès Perrin; Helene Lasolle; Jean-Christophe Lifante; Françoise Borson-Chazot; Claire Bournaud
Journal: Cancers (Basel) Date: 2022-05-24 Impact factor: 6.575

4. Evaluation of the expression levels of BRAF^V600E mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay.

Authors: Tien Viet Tran; Kien Xuan Dang; Quynh Huong Pham; Ung Dinh Nguyen; Nhung Thi Trang Trinh; Luong Van Hoang; Son Anh Ho; Ba Van Nguyen; Duc Trong Nguyen; Dung Tuan Trinh; Dung Ngoc Tran; Arto Orpana; Ulf-Håkan Stenman; Jakob Stenman; Tho Huu Ho
Journal: BMC Cancer Date: 2020-05-01 Impact factor: 4.430

5. Utility of droplet digital polymerase chain reaction for TERT and BRAF mutational profiling of thyroid nodules.

Authors: Brandon R Rosvall; Morris Kostiuk; Jordana Williams; Ashlee Matkin; Jeffrey Harris; Hadi Seikaly; Daniel A O'Connell; Vincent L Biron
Journal: BMC Cancer Date: 2021-10-26 Impact factor: 4.430

Review 6. Papillary Thyroid Cancer Prognosis: An Evolving Field.

Authors: Salvatore Ulisse; Enke Baldini; Augusto Lauro; Daniele Pironi; Domenico Tripodi; Eleonora Lori; Iulia Catalina Ferent; Maria Ida Amabile; Antonio Catania; Filippo Maria Di Matteo; Flavio Forte; Alberto Santoro; Piergaspare Palumbo; Vito D'Andrea; Salvatore Sorrenti
Journal: Cancers (Basel) Date: 2021-11-07 Impact factor: 6.639

Review 10. Telomerase reverse transcriptase promoter mutations in thyroid carcinomas: implications in precision oncology-a narrative review.

Authors: Xiaotian Yuan; Tiantian Liu; Dawei Xu
Journal: Ann Transl Med Date: 2020-10